Emily Booth, PA
Physician Assistant · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 10 years
- Graduated 2016
Offices
1 location · UCSF Dept of Surgery · 211 clinicians in this group
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Emily Booth’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Drugs they prescribed that Part D paid
$339,580
Pharmacies billed $339,580 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,138) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
870 generic and 268 brand-name prescriptions · $339,580 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 94 | $128,105 | $1,363 |
| Jardiance | 62 | $88,568 | $1,429 |
| Entresto | 62 | $63,834 | $1,030 |
| Xarelto | 26 | $37,713 | $1,450 |
| Isosorbide Dinitrate | 23 | $1,990 | $87 |
See all 26 drugs
| Eliquis | 94 | $128,105 | $1,363 |
| Jardiance | 62 | $88,568 | $1,429 |
| Entresto | 62 | $63,834 | $1,030 |
| Xarelto | 26 | $37,713 | $1,450 |
| Isosorbide Dinitrate | 23 | $1,990 | $87 |
| Metoprolol | 105 | $1,536 | $15 |
| Bumetanide | 16 | $1,265 | $79 |
| Atorvastatin | 83 | $668 | $8 |
| Furosemide | 103 | $639 | $6 |
| Amiodarone | 17 | $623 | $37 |
| Carvedilol | 108 | $581 | $5 |
| Ezetimibe | 13 | $499 | $38 |
| Rosuvastatin | 37 | $480 | $13 |
| Diltiazem 24hr Er (Cd) | 13 | $432 | $33 |
| Hydralazine | 36 | $348 | $10 |
| Spironolactone | 75 | $340 | $5 |
| Potassium Chloride | 15 | $225 | $15 |
| Losartan | 51 | $214 | $4 |
| Metoprolol | 30 | $206 | $7 |
| Clopidogrel | 36 | $203 | $6 |
| Digoxin | 11 | $189 | $17 |
| Isosorbide Mononitrate Er | 13 | $157 | $12 |
| Torsemide | 11 | $134 | $12 |
| Lisinopril | 34 | $122 | $4 |
| Nitroglycerin | 11 | $99 | $9 |
| Amlodipine Besylate | 15 | $45 | $3 |
Year by year
| 2024 | 1,138 | 204 | 0% (0) | 24% | $339,580 |
| 2023 | 782 | 203 | 0% (0) | 17% | $189,418 |
| 2022 | 594 | 185 | 0% (0) | 18% | $122,790 |
| 2021 | 525 | 162 | 0% (0) | 24% | $83,584 |
| 2020 | 596 | 166 | 0% (0) | 29% | $61,739 |
| 2019 | 702 | 163 | 0% (0) | 22% | $35,295 |
| 2018 | 82 | 36 | 0% (0) | 15% | $3,108 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Eliquis | 86 | $114,793 | $1,335 |
| Xarelto | 20 | $32,679 | $1,634 |
| Amiodarone | 31 | $2,918 | $94 |
| Isosorbide Dinitrate | 20 | $2,216 | $111 |
| Isosorbide Mononitrate Er | 39 | $2,132 | $55 |
| Atorvastatin | 82 | $2,120 | $26 |
| Metoprolol | 68 | $1,440 | $21 |
| Lisinopril | 41 | $1,047 | $26 |
| Amlodipine Besylate | 44 | $980 | $22 |
| Carvedilol | 49 | $788 | $16 |
| Diltiazem 24hr Er (Cd) | 19 | $674 | $35 |
| Digoxin | 19 | $477 | $25 |
| Metoprolol | 41 | $425 | $10 |
| Losartan | 22 | $334 | $15 |
| Rosuvastatin | 22 | $308 | $14 |
| Hydralazine | 22 | $300 | $14 |
| Clopidogrel | 17 | $300 | $18 |
| Furosemide | 37 | $265 | $7 |
| Nitroglycerin | 20 | $228 | $11 |
2022: 16 drugs
| Eliquis | 68 | $82,978 | $1,220 |
| Amiodarone | 26 | $1,830 | $70 |
| Isosorbide Dinitrate | 13 | $1,711 | $132 |
| Isosorbide Mononitrate Er | 35 | $1,362 | $39 |
| Atorvastatin | 62 | $1,249 | $20 |
| Metoprolol | 49 | $954 | $19 |
| Rosuvastatin | 11 | $763 | $69 |
| Diltiazem 24hr Er (Cd) | 17 | $620 | $36 |
| Carvedilol | 29 | $420 | $14 |
| Amlodipine Besylate | 40 | $416 | $10 |
| Metoprolol | 34 | $336 | $10 |
| Nitroglycerin | 13 | $282 | $22 |
| Furosemide | 34 | $274 | $8 |
| Losartan | 15 | $271 | $18 |
| Lisinopril | 23 | $265 | $12 |
| Clopidogrel | 17 | $225 | $13 |
2021: 15 drugs
| Eliquis | 48 | $47,548 | $991 |
| Isosorbide Dinitrate | 27 | $2,855 | $106 |
| Atorvastatin | 66 | $1,555 | $24 |
| Amiodarone | 21 | $879 | $42 |
| Metoprolol | 32 | $729 | $23 |
| Isosorbide Mononitrate Er | 26 | $609 | $23 |
| Furosemide | 47 | $418 | $9 |
| Nitroglycerin | 22 | $333 | $15 |
| Amlodipine Besylate | 29 | $255 | $9 |
| Clopidogrel | 15 | $225 | $15 |
| Metoprolol | 38 | $217 | $6 |
| Losartan | 14 | $170 | $12 |
| Carvedilol | 13 | $165 | $13 |
| Lisinopril | 15 | $103 | $7 |
| Hydrochlorothiazide | 15 | $51 | $3 |
2020: 18 drugs
| Eliquis | 34 | $30,717 | $903 |
| Xarelto | 14 | $17,597 | $1,257 |
| Isosorbide Dinitrate | 43 | $3,077 | $72 |
| Atorvastatin | 57 | $789 | $14 |
| Furosemide | 84 | $554 | $7 |
| Amiodarone | 22 | $551 | $25 |
| Metoprolol | 25 | $531 | $21 |
| Isosorbide Mononitrate Er | 26 | $447 | $17 |
| Nitroglycerin | 24 | $388 | $16 |
| Losartan | 33 | $349 | $11 |
| Rosuvastatin | 12 | $344 | $29 |
| Metoprolol | 39 | $270 | $7 |
| Diltiazem 24hr Er (Cd) | 11 | $268 | $24 |
| Clopidogrel | 18 | $209 | $12 |
| Carvedilol | 21 | $137 | $7 |
| Amlodipine Besylate | 25 | $128 | $5 |
| Lisinopril | 25 | $123 | $5 |
| Hydrochlorothiazide | 16 | $83 | $5 |
2019: 16 drugs
| Eliquis | 25 | $15,795 | $632 |
| Isosorbide Dinitrate | 30 | $2,552 | $85 |
| Metoprolol | 49 | $1,117 | $23 |
| Atorvastatin | 75 | $947 | $13 |
| Amiodarone | 16 | $490 | $31 |
| Nitroglycerin | 29 | $447 | $15 |
| Furosemide | 83 | $412 | $5 |
| Amlodipine Besylate | 54 | $398 | $7 |
| Losartan | 33 | $381 | $12 |
| Carvedilol | 42 | $374 | $9 |
| Metoprolol | 45 | $252 | $6 |
| Clopidogrel | 25 | $240 | $10 |
| Isosorbide Mononitrate Er | 19 | $182 | $10 |
| Lisinopril | 36 | $157 | $4 |
| Hydrochlorothiazide | 21 | $90 | $4 |
| Atenolol | 12 | $80 | $7 |
2018: 1 drug
| Atorvastatin | 12 | $108 | $9 |
Money from drug and device companies
$101 in 2025
| 2025 | 1 | 1 | None | $101 |
| 2024 | 1 | 1 | None | $39 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Signia | $101 | 1 payment
|
See the published payment
| Medtronic | Meals · 2025-10-02 | Signia | $101 |
See earlier years (2024)
2024: $39
| iRhythm Technologies | Zio Xt Patch | $39 | 1 payment
|
Professional record
- NPI
- 1720531148
- Group
- UCSF Dept of Surgery
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant, medical (363AM0700X); Physician assistant (363A00000X)
- Mailing address
- 400 Parnassus Ave, San Francisco, CA, 94143
- NPI first listed
- 2016-08-02
- NPI last updated
- 2025-03-11
- NPI record certified
- 2025-03-11
This is when the NPI record was last certified, not a medical board exam.